Baxter Articles
Iraq's Red Crescent demands $238M blood compensation
2 April 2007
Indonesia settles IP rights claim over H5N1 strains
5 March 2007
Hylenex may have role in analgesia, says trial
26 February 2007
Jerini and Baxter expand hemophilia R&D accord
12 February 2007
BioVeris completes additional vaccine license
5 February 2007
Baxter's 4th-qtr net earnings up 47%
5 February 2007
Lipoxen gets $1M license signing fee from Baxter
22 December 2006
Baxter in flu contract with Austria
27 November 2006
Stock Commentary - Europe - week to Nov 20, 2006
27 November 2006
Genzyme Japan appoints general manager
23 October 2006
Texas 'overcharged' by three drug firms
13 June 2006
Innovata's Adept gets FDA approvable letter
12 June 2006
Innovata transforms into profitable firm
12 June 2006
S-P's Temodar, Baxter's Feiba etc OKed in Japan
15 May 2006
Largest single vaccine donation reaches Islamabad
20 March 2006
Stock Commentary - New York week to Feb 13, 2006
20 February 2006
Baxter/Halozyme see good data on SubQ plus Hylenex
20 February 2006
GSK buys Pliva Research Inst for $50M
20 February 2006
Innovata agrees Adept licensing deal
9 January 2006
Baxter launches sevoflurane in China
19 December 2005
Halozyme/Baxter get FDA appro for Hylenex
12 December 2005
Peregrine unit begins first commercial-stage project
12 December 2005
Baxter's IVIg receives European approval
5 December 2005
Baxter gets FDA go ahead for Ceftriaxone
5 September 2005
Acambis welcomes US RFP for MVA vaccine
22 August 2005
BioVeris licenses Baxter vaccine portfolio
22 August 2005
Halozyme/Baxter sign EU Hylenex deal
15 August 2005
Baxter's 2nd-qtr 2005 sales jump 8%
1 August 2005
Acambis starts Ph II trial of smallpox vacc
25 July 2005
ML Labs to buy Quadrant for L46.7M
27 June 2005
Cerus and BioOne join forces on Intercept
13 June 2005
Baxter reiterates full-year 2005 outlook
6 June 2005
FDA clears APP's generic Esmolol
16 May 2005
Baxter sees 8% sales growth in 1st qtr
22 April 2005
Halozyme and Baxter expand Enhanze deal
18 April 2005
Appointments at Baxter International
4 April 2005
Baxter's Advate shows good market acceptance
14 March 2005
Appointments and promotions at MedImmune
28 February 2005
TKT names Theresa Heggie as general manager, Europe
14 February 2005
Hitch for Pennsylvania drug pricing suit
14 February 2005
Baxter's Advate gets expanded approval
10 January 2005
US government dishes out vaccine contracts to foreign firms
11 October 2004
Acambis and Baxter's MVA on FDA fast-track
4 October 2004
France to reimburse Baxter's Advate
30 August 2004
Spectrum licenses AEterna's D-63153
23 August 2004
Morphotek and Baxter sign accord
16 August 2004
NeoPharm appoints Gregory Young as CEO
2 August 2004
Baxter to restate results, revises 2004 forecast
2 August 2004
John Greisch promoted to CFO of Baxter International
28 June 2004
Stock Commentary - New York
7 June 2004
Baxter gets FDA warning on ADVATE promotion
7 June 2004
Acambis to get $19M compensation from Baxter
31 May 2004
Stock Commentary - Europe
31 May 2004
Xoma's 1st-qtr 2004 net loss widens 54%
24 May 2004
Jerini and Baxter extend alliance
10 May 2004
Baxter's sales climb 11% for 1st-qtr 2004
3 May 2004
Former Abbott president joins Baxter
26 April 2004
Global peripheral neuropathy market worth $1B by 2012
19 April 2004
InterMune unveils its path for the future
12 April 2004
Baxter and InterMune to co-promote Aralast
5 April 2004
Xoma sees net loss jump as revenues fall
22 March 2004
Edwards Lifesciences concludes arbitration with Baxter
26 January 2004
New Chemical Entities in 2003
19 January 2004
Stock Commentary - Europe
5 January 2004
Baxter sells its 20% stake in Acambis
5 January 2004
Baxter sells its 20% stake in Acambis
5 January 2004
Stock Commentary - Europe
22 December 2003
Acambis files vaccine BLA with FDA
22 December 2003
Stock Commentary - New York
15 December 2003
Aventis disposes of Behring unit with $925M sale to Australia's CSL
15 December 2003
Baxter R&D moves into Vienna facility
8 December 2003
Jerini passes two research milestones under Baxter alliance
17 November 2003
Baxter/Aventis receive $18M SARS funding
6 October 2003
Baxter and Cerus hold red blood cell Ph III trial
15 September 2003
FDA approves Baxter hemophilia drug
4 August 2003
Baxter shifts Bioset production to Malta
28 July 2003
Baxter to sell its renal services components
21 July 2003
Baxter/Abbott patent dispute reinstated
14 July 2003
XOMA closes license deal with Baxter
14 July 2003
Agis obtains FDA approval for Promethazine
7 July 2003
Baxter to slash 2,500 jobs in search for profit
7 July 2003
Baxter Healthcare expands contract manufacturing
16 June 2003
Mitsubishi Pharma latest in blood law suit
9 June 2003
11 new drugs added to Japan's NHI price list
9 June 2003
Tokyo pharma stocks - week to May 12
19 May 2003
ML Labs lifted by US Extraneal launch
12 May 2003
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
